**Supplementary Table 1**.Clinicopathologic Characteristics of 85 glioma patients

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Value** | **Percentage** |
| Total samples (n) | 85 |  |
| Sex(n) |  |  |
| Male | 47 | 55.3% |
| Female | 38 | 44.7% |
| Median age, years(range) | 47(23-72) |  |
| EBRT dose(Gy) | 60 |  |
| Meidan KPS(range) | 80(40-90) |  |
| Progression-free duration(range) | 8(3-16) |  |

**NOTE:** A summary of the clinical characteristics of the study population. The trial involved 85 specimens.

**Abbreviations:** EBRT, external-beam radiotherapy; KPS, Karnofsky performance status.

**Supplementary Table 2.** Molecular features of the 85 GBM samples

|  |  |  |  |
| --- | --- | --- | --- |
|  | **MTDH high** | **MTDH low** | ***p* value** |
| Total samples, n (%) (n=85) | 75 (88) | 10 (12) | <0.001 |
| FOXM1 expression (high/low) | 68/7 | 3/7 | <0.001 |
| VEGF expression (high/low) | 63/12 | 5/5 | <0.001 |
| MMP-2 expression (high/low) | 61/14 | 6/4 | <0.001 |
| skp2 expression (high/low) | 58/17 | 5/5 | <0.05 |
| cdc25B expression (high/low) | 60/15 | 3/7 | <0.05 |
| MGMT promoter methylation(unmethylated/methylated) | 43/32 | 5/5 | >0.05 |
| IDH mutation (mutation/wild-type) | 39/36 | 4/6 | >0.05 |

**Supplementary Table 3**. PCR primers used in real-time RT-PCR and ChIP assay

|  |  |
| --- | --- |
| ***FOXM1* forward:**TGCCCAGCAGTCTCTTACCT | ***FOXM1* reverse:**CTACCCACCTTCTGGCAGTC |
| ***MTDH* forward:** TGCCTCCTTCACAGACCAA | ***MTDH* reverse:**TCGGCTGCAGATGAGATAG |
| ***GAPDH* forward:**AATCCCATCACCATCTTCCA | ***GAPDH* reverse:** TGGACTCCACGACGTACTCA |
| ***VEGF* promoter forward:**CCCCTTTCCAAAGCCCATTCC | ***VEGF* promoter reverse:**CCTTCTCCCCGCTCCAACACCC |
| ***MMP-2* forward:**AACCAGTCTTGCCCAATTTC | ***MMP-2* reverse:**CCTTCTGCAAATGTGTAAGCC |
| ***Skp2* promoter forward:**AAT TAG CCA GGT GTG GTA GCG G | ***Skp2* promoter reverse:**CAG GCT TCA GTG TAA TGG CAC G |